{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T18:36:33Z","timestamp":1793903793789,"version":"4.8.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","atherosclerosis-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.atherosclerosis.2017.08.015","type":"journal-article","created":{"date-parts":[[2017,8,23]],"date-time":"2017-08-23T04:02:00Z","timestamp":1503460920000},"page":"234-239","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["Soluble form of receptor for advanced glycation end products and incidence of new cardiovascular events among patients with cardiovascular disease"],"prefix":"10.1016","volume":"266","author":[{"given":"Stefan","family":"Reichert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Triebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander Navarrete","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britt","family":"Hofmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-G\u00fcnter","family":"Schaller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Schlitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2017.08.015_bib1","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1093\/eurheartj\/ehw334","article-title":"Cardiovascular disease in Europe: epidemiological update 2016","volume":"37","author":"Townsend","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2017.08.015_bib2","doi-asserted-by":"crossref","first-page":"e81400","DOI":"10.1371\/journal.pone.0081400","article-title":"NT-proBNP best predictor of cardiovascular events and cardiovascular mortality in secondary prevention in very old age: the Leiden 85-plus study","volume":"8","author":"van Peet","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.atherosclerosis.2017.08.015_bib3","doi-asserted-by":"crossref","first-page":"937","DOI":"10.2174\/1381612822666161006143032","article-title":"Therapeutic interventions for advanced glycation-end products and its receptor-mediated cardiovascular disease","volume":"23","author":"Prasad","year":"2017","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.atherosclerosis.2017.08.015_bib4","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1096\/fj.08-109033","article-title":"A\u00a0soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10)","volume":"22","author":"Raucci","year":"2008","journal-title":"FASEB J."},{"key":"10.1016\/j.atherosclerosis.2017.08.015_bib5","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1096\/fj.07-9909com","article-title":"Identification, classification, and expression of RAGE gene splice variants","volume":"22","author":"Hudson","year":"2008","journal-title":"FASEB J."},{"key":"10.1016\/j.atherosclerosis.2017.08.015_bib6","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/2012","article-title":"Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts","volume":"4","author":"Park","year":"1998","journal-title":"Nat. Med."},{"key":"10.1016\/j.atherosclerosis.2017.08.015_bib7","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1161\/01.CIR.0000039325.03698.36","article-title":"RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice","volume":"106","author":"Bucciarelli","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2017.08.015_bib8","first-page":"941","article-title":"Inverse association between circulating levels of soluble receptor for advanced glycation end-products and coronary plaque burden","volume":"19","author":"Basta","year":"2012","journal-title":"J.\u00a0Atheroscler. Thromb."},{"key":"10.1016\/j.atherosclerosis.2017.08.015_bib9","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.2337\/dc09-0053","article-title":"Association between circulating soluble receptor for advanced glycation end products and atherosclerosis: observations from the dallas heart study","volume":"32","author":"Lindsey","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2017.08.015_bib10","doi-asserted-by":"crossref","first-page":"e70834","DOI":"10.1371\/journal.pone.0070834","article-title":"Association of four genetic polymorphisms of AGER and its circulating forms with coronary artery disease: a meta-analysis","volume":"8","author":"Peng","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.atherosclerosis.2017.08.015_bib11","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1161\/01.ATV.0000160342.20342.00","article-title":"Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men","volume":"25","author":"Falcone","year":"2005","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2017.08.015_bib12","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1002\/clc.20815","article-title":"Soluble receptors for advanced glycation end products (sRAGE) as a predictor of restenosis following percutaneous coronary intervention","volume":"33","author":"McNair","year":"2010","journal-title":"Clin. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2017.08.015_bib13","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.atherosclerosis.2011.01.024","article-title":"Association of serum soluble receptor for advanced glycation end-products with subclinical cerebrovascular disease: the Northern Manhattan Study (NOMAS)","volume":"216","author":"Hudson","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2017.08.015_bib14","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.atherosclerosis.2013.01.016","article-title":"Circulating soluble RAGE as a predictive biomarker of cardiovascular event risk in patients with type 2 diabetes","volume":"227","author":"Fujisawa","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2017.08.015_bib15","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.atherosclerosis.2011.05.023","article-title":"Association of increased S100B, S100A6 and S100P in serum levels with acute coronary syndrome and also with the severity of myocardial infarction in cardiac tissue of rat models with ischemia-reperfusion injury","volume":"217","author":"Cai","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2017.08.015_bib16","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.2337\/db11-0291","article-title":"Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 diabetes: an analysis from the CARDS trial","volume":"60","author":"Colhoun","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.atherosclerosis.2017.08.015_bib17","doi-asserted-by":"crossref","first-page":"e114519","DOI":"10.1371\/journal.pone.0114519","article-title":"Prediction of cardiovascular events in statin-treated stable coronary patients of the treating to new targets randomized controlled trial by lipid and non-lipid biomarkers","volume":"9","author":"Arsenault","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.atherosclerosis.2017.08.015_bib18","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1007\/s00391-013-0523-7","article-title":"Intraoperative sRAGE kinetics. a new age-related outcome predictor of cardiac surgery","volume":"47","author":"Simm","year":"2014","journal-title":"Z\u00a0Gerontol. Geriatr."},{"key":"10.1016\/j.atherosclerosis.2017.08.015_bib19","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1111\/jcpe.12611","article-title":"Periodontal conditions and incidence of new cardiovascular events among patients with coronary vascular disease","volume":"43","author":"Reichert","year":"2016","journal-title":"J.\u00a0Clin. Period"},{"key":"10.1016\/j.atherosclerosis.2017.08.015_bib20","doi-asserted-by":"crossref","first-page":"979","DOI":"10.2174\/138161208784139684","article-title":"The role of AGEs in cardiovascular disease","volume":"14","author":"Jandeleit-Dahm","year":"2008","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.atherosclerosis.2017.08.015_bib21","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3132\/dvdr.2009.002","article-title":"Receptor for advanced glycation end-products (RAGE) and soluble RAGE (sRAGE): cardiovascular implications","volume":"6","author":"Lindsey","year":"2009","journal-title":"Diab Vasc. Dis. Res."},{"issue":"Suppl.14","key":"10.1016\/j.atherosclerosis.2017.08.015_bib22","first-page":"70","article-title":"The epidemiological evidence behind the association between periodontitis and incident atherosclerotic cardiovascular disease","volume":"40","author":"Dietrich","year":"2013","journal-title":"J.\u00a0Clin. Periodontol."},{"key":"10.1016\/j.atherosclerosis.2017.08.015_bib23","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1007\/s00125-011-2186-5","article-title":"Soluble receptor for AGE (RAGE) is a novel independent predictor of all-cause and cardiovascular mortality in type 1 diabetes","volume":"54","author":"Thomas","year":"2011","journal-title":"Diabetologia"},{"key":"10.1016\/j.atherosclerosis.2017.08.015_bib24","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.2337\/db09-1509","article-title":"Higher plasma soluble Receptor for Advanced Glycation End Products (sRAGE) levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study","volume":"59","author":"Nin","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.atherosclerosis.2017.08.015_bib25","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1007\/s00125-006-0394-1","article-title":"Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes","volume":"49","author":"Tan","year":"2006","journal-title":"Diabetologia"},{"key":"10.1016\/j.atherosclerosis.2017.08.015_bib26","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.metabol.2006.05.007","article-title":"Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects","volume":"55","author":"Yamagishi","year":"2006","journal-title":"Metabolism"},{"key":"10.1016\/j.atherosclerosis.2017.08.015_bib27","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1373\/clinchem.2005.051961","article-title":"Increased serum concentrations of soluble receptor for advanced glycation endproducts in patients with type 1 diabetes","volume":"51","author":"Challier","year":"2005","journal-title":"Clin. Chem."},{"key":"10.1016\/j.atherosclerosis.2017.08.015_bib28","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/dmrr.690","article-title":"Elevation of soluble form of receptor for advanced glycation end products (sRAGE) in diabetic subjects with coronary artery disease","volume":"23","author":"Nakamura","year":"2007","journal-title":"Diabetes Metab. Res. Rev."},{"key":"10.1016\/j.atherosclerosis.2017.08.015_bib29","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/13813450802033818","article-title":"Soluble RAGE, diabetic nephropathy and genetic variability in the AGER gene","volume":"114","author":"Kankova","year":"2008","journal-title":"Arch. Physiol. Biochem."},{"key":"10.1016\/j.atherosclerosis.2017.08.015_bib30","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1093\/ndt\/gfu282","article-title":"Association of plasma levels of soluble receptor for advanced glycation end products and risk of kidney disease: the atherosclerosis risk in communities study","volume":"30","author":"Rebholz","year":"2015","journal-title":"Nephrol. Dial. Transpl."},{"key":"10.1016\/j.atherosclerosis.2017.08.015_bib31","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.clinbiochem.2014.12.022","article-title":"Dynamic changes in sRAGE levels and relationship with cardiac function in STEMI patients","volume":"48","author":"Jensen","year":"2015","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.atherosclerosis.2017.08.015_bib32","doi-asserted-by":"crossref","first-page":"657607","DOI":"10.1155\/2014\/657607","article-title":"Soluble form of receptor for advanced glycation end products is associated with obesity and metabolic syndrome in adolescents","volume":"2014","author":"He","year":"2014","journal-title":"Int. J. Endocrinol."},{"key":"10.1016\/j.atherosclerosis.2017.08.015_bib33","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1089\/met.2015.0078","article-title":"Serum levels of sRAGE are associated with body measurements, but not glycemic parameters in patients with prediabetes","volume":"14","author":"Guclu","year":"2016","journal-title":"Metab. Syndr. Relat. Disord."},{"key":"10.1016\/j.atherosclerosis.2017.08.015_bib34","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.metabol.2017.02.008","article-title":"Racial differences in circulating levels of the soluble receptor for advanced glycation endproducts in middle-aged and older adults","volume":"70","author":"Brinkley","year":"2017","journal-title":"Metabolism"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915017312376?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915017312376?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,28]],"date-time":"2018-08-28T06:58:35Z","timestamp":1535439515000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915017312376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":34,"alternative-id":["S0021915017312376"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2017.08.015","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Soluble form of receptor for advanced glycation end products and incidence of new cardiovascular events among patients with cardiovascular disease","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2017.08.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}